Valneva SE (VLA.PA)
EUR 1.83
(2.93%)
EUR 1.83
(2.93%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 208.81 Million EUR | 37.04% |
| 2022 | 152.38 Million EUR | 32.9% |
| 2021 | 114.65 Million EUR | 8.73% |
| 2020 | 105.45 Million EUR | 23.75% |
| 2019 | 85.21 Million EUR | 47.94% |
| 2018 | 57.6 Million EUR | -19.43% |
| 2017 | 71.49 Million EUR | -13.34% |
| 2016 | 82.5 Million EUR | -19.32% |
| 2015 | 102.25 Million EUR | 39.78% |
| 2014 | 73.15 Million EUR | 2.63% |
| 2013 | 71.28 Million EUR | 961.69% |
| 2012 | 6.71 Million EUR | -1.21% |
| 2011 | 6.79 Million EUR | -0.03% |
| 2010 | 6.79 Million EUR | 6.47% |
| 2009 | 6.38 Million EUR | 37.85% |
| 2008 | 4.63 Million EUR | 25.53% |
| 2007 | 3.69 Million EUR | 10.58% |
| 2006 | 3.33 Million EUR | 9.02% |
| 2005 | 3.06 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 211.67 Million EUR | 1.37% |
| 2024 Q2 | 209.63 Million EUR | -0.96% |
| 2023 Q1 | 152.72 Million EUR | 0.23% |
| 2023 Q3 | 194.5 Million EUR | 30.34% |
| 2023 FY | 208.81 Million EUR | 37.04% |
| 2023 Q4 | 208.81 Million EUR | 7.36% |
| 2023 Q2 | 149.23 Million EUR | -2.29% |
| 2022 Q3 | 161.61 Million EUR | 21.04% |
| 2022 Q4 | 152.38 Million EUR | -5.72% |
| 2022 FY | 152.38 Million EUR | 32.9% |
| 2022 Q1 | 115.52 Million EUR | 0.75% |
| 2022 Q2 | 133.52 Million EUR | 15.58% |
| 2021 Q2 | 111.48 Million EUR | 5.17% |
| 2021 Q4 | 114.65 Million EUR | 0.0% |
| 2021 Q1 | 106 Million EUR | 0.53% |
| 2021 FY | 114.65 Million EUR | 8.73% |
| 2020 Q4 | 105.45 Million EUR | -5.23% |
| 2020 Q1 | 99.28 Million EUR | 16.51% |
| 2020 Q2 | 112.95 Million EUR | 13.76% |
| 2020 Q3 | 111.26 Million EUR | -1.49% |
| 2020 FY | 105.45 Million EUR | 23.75% |
| 2019 Q4 | 85.21 Million EUR | 1.66% |
| 2019 FY | 85.21 Million EUR | 47.94% |
| 2019 Q3 | 83.82 Million EUR | 13.7% |
| 2019 Q2 | 73.71 Million EUR | -3.64% |
| 2019 Q1 | 76.49 Million EUR | 32.81% |
| 2018 FY | 57.6 Million EUR | -19.43% |
| 2018 Q1 | 66.51 Million EUR | -6.97% |
| 2018 Q3 | 60.34 Million EUR | -2.65% |
| 2018 Q4 | 57.6 Million EUR | -4.55% |
| 2018 Q2 | 61.98 Million EUR | -6.81% |
| 2017 Q2 | 74.07 Million EUR | -1.69% |
| 2017 Q1 | 75.34 Million EUR | -8.67% |
| 2017 Q4 | 71.49 Million EUR | 2.27% |
| 2017 FY | 71.49 Million EUR | -13.34% |
| 2017 Q3 | 69.91 Million EUR | -5.62% |
| 2016 Q1 | 82.42 Million EUR | -19.39% |
| 2016 Q2 | 80.46 Million EUR | -2.38% |
| 2016 Q3 | 80.2 Million EUR | -0.33% |
| 2016 Q4 | 82.5 Million EUR | 2.87% |
| 2016 FY | 82.5 Million EUR | -19.32% |
| 2015 Q4 | 102.25 Million EUR | 16.21% |
| 2015 FY | 102.25 Million EUR | 39.78% |
| 2015 Q2 | 89.25 Million EUR | -1.75% |
| 2015 Q1 | 90.84 Million EUR | 24.18% |
| 2015 Q3 | 87.99 Million EUR | -1.41% |
| 2014 Q2 | 70.59 Million EUR | -1.03% |
| 2014 FY | 73.15 Million EUR | 2.63% |
| 2014 Q4 | 73.15 Million EUR | 2.24% |
| 2014 Q3 | 71.55 Million EUR | 1.36% |
| 2014 Q1 | 71.32 Million EUR | 0.06% |
| 2013 FY | 71.28 Million EUR | 961.69% |
| 2013 Q1 | - EUR | -100.0% |
| 2013 Q2 | 79.39 Million EUR | 0.0% |
| 2013 Q3 | 51.59 Million EUR | -35.02% |
| 2013 Q4 | 71.28 Million EUR | 38.16% |
| 2012 Q4 | 6.71 Million EUR | 0.0% |
| 2012 Q2 | 6.21 Million EUR | 0.0% |
| 2012 FY | 6.71 Million EUR | -1.21% |
| 2011 FY | 6.79 Million EUR | -0.03% |
| 2011 Q4 | 6.79 Million EUR | 0.0% |
| 2011 Q2 | 7.61 Million EUR | 0.0% |
| 2010 FY | 6.79 Million EUR | 6.47% |
| 2010 Q4 | 6.79 Million EUR | 0.0% |
| 2010 Q2 | 6.94 Million EUR | 0.0% |
| 2009 FY | 6.38 Million EUR | 37.85% |
| 2009 Q4 | 6.38 Million EUR | 0.0% |
| 2008 FY | 4.63 Million EUR | 25.53% |
| 2007 FY | 3.69 Million EUR | 10.58% |
| 2006 FY | 3.33 Million EUR | 9.02% |
| 2005 FY | 3.06 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -6059.764% |
| ABIVAX Société Anonyme | 55.46 Million EUR | -276.489% |
| Adocia SA | 13.08 Million EUR | -1495.477% |
| Aelis Farma SA | 4.03 Million EUR | -5071.273% |
| Biophytis S.A. | 8.27 Million EUR | -2424.982% |
| Advicenne S.A. | 17.42 Million EUR | -1098.37% |
| genOway Société anonyme | 7.23 Million EUR | -2786.829% |
| IntegraGen SA | 1.12 Million EUR | -18465.795% |
| Medesis Pharma S.A. | 1.2 Million EUR | -17301.333% |
| Neovacs S.A. | 650 Thousand EUR | -32025.538% |
| NFL Biosciences SA | 62.17 Thousand EUR | -335757.432% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -4693.196% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -7585.991% |
| Sensorion SA | 2.86 Million EUR | -7178.895% |
| Theranexus Société Anonyme | 3.64 Million EUR | -5631.946% |
| TME Pharma N.V. | 1.16 Million EUR | -17808.748% |
| Valbiotis SA | 6.87 Million EUR | -2935.999% |
| TheraVet SA | 1.15 Million EUR | -17903.443% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | -2220.693% |
| argenx SE | 18.1 Million EUR | -1053.343% |
| BioSenic S.A. | 28.16 Million EUR | -641.508% |
| Celyad Oncology SA | 902 Thousand EUR | -23050.333% |
| DBV Technologies S.A. | 13.01 Million USD | -1503.982% |
| Galapagos NV | 9.59 Million EUR | -2076.073% |
| Genfit S.A. | 70.17 Million EUR | -197.552% |
| GeNeuro SA | 7.73 Million EUR | -2598.648% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | -3844.39% |
| Innate Pharma S.A. | 39.89 Million EUR | -423.44% |
| Inventiva S.A. | 37.4 Million EUR | -458.227% |
| MaaT Pharma SA | 14.07 Million EUR | -1383.595% |
| MedinCell S.A. | 58.96 Million EUR | -254.16% |
| Nanobiotix S.A. | 50.56 Million EUR | -312.965% |
| Onward Medical N.V. | 16.87 Million EUR | -1137.501% |
| Oryzon Genomics S.A. | 13.68 Million EUR | -1425.625% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | -355.92% |
| Oxurion NV | 12.33 Million EUR | -1593.011% |
| Pharming Group N.V. | 155.29 Million EUR | -34.465% |
| Poxel S.A. | 46.9 Million EUR | -345.237% |
| GenSight Biologics S.A. | 18.42 Million EUR | -1033.145% |
| Transgene SA | 1.25 Million EUR | -16512.251% |
| Financière de Tubize SA | 79.2 Million EUR | -163.657% |
| UCB SA | 3.03 Billion EUR | 93.127% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -549415.789% |